Dangers from Methylprednisolone Acetate Therapy by Intraspinal Injection
Arch Neurol 45:804-806, Nelson,D.A., 1988
The Optic Nerve Should Graduate to Be the Fifth Lesion Site for the Diagnosis of Multiple Sclerosis
Neurol 102:e207919, Galetta,S. & Brownlee, W., 2024
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Mlutiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-Up
Arch Neurol 65:727-732, The Optic Neuritis Study Group, 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Polyneuropathy Associated with Interferon Beta Treatment in Patients with Multiple Sclerosis
Neurol 65:456-458, Ekstein,D.,et al, 2005
Clinical and MRI Outcome after Autologous Hematoipoietic Stem Cell Transplantation in MS
Neurol 62:282-284,168, Saiz,A.,et al, 2004
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Interferon Beta-1a for Brain Tissue Loss in Patients at Presentation with Syndromes Suggestive of Multiple Sclerosis: A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 364:1489-1496,1463, Filippi,M.,et al, 2004
Evidence for Widespread Axonal Damage at the Earliest Clinical Stage of Multiple Sclerosis
Brain 126:433-437, Filippi,M.,et al, 2003
High- and Low-Risk Profiles for the Development of Multiple Sclerosis Within 10 Years After Optic Neuritis
Arch Ophthalmol 121:944-949, Optic Neuritis Study Group, 2003
Randomised Double Blind Controlled Trial of Cyclosporin in Multiple Sclerosis
JNNP 52:559-565, Rudge,P.,et al, 1989
Important Advances in Clinical Medicine
West J Med 123:128, Mosier,J.M.,et al, 1975